Virtual Library

Start Your Search

S. Altin



Author of

  • +

    P1.04 - Poster Session with Presenters Present (ID 456)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Pulmonology
    • Presentations: 1
    • +

      P1.04-017 - The Survival of Our Patients Diagnosed with Lung Cancer in 2013 (ID 5187)

      14:30 - 15:45  |  Author(s): S. Altin

      • Abstract

      Background:
      Lung cancer is an important health problem. To investigate the survival of our patients diagnosed in our hospital with lung cancer and the situations that effect.

      Methods:
      Using the data processing and archive system of our hospital , patients were examined who had operated with C34 code in 2013. The rates of survival were calculated using Kaplan-Meier Method and compared with Long-rank method. The influence of age on survival was analysed with Cox’s proportional hazards regression model. For multivariate analysis Cox’s proportional hazards regression model also used. The level of P<0.05 accepted as significant.

      Results:
      1563(83.5%) of 1871 patients were male and 308 of the were female and their average age were found as 62.5 years, the average age in male was 62.7 while 61.4 in female. Median age was 62. The rate of M/F was calculated as 5.1, but there were no difference in terms of the average age(p>0.05). We had 16 male and 11 female patients were about 27(1.4%), under the age of 40. As a histological type, 717(38.3%) were squamous carcinoma, 692(37%) were adenocarcinoma, 288(15,4%) were small cell, 174(9.3%) unidentified cell malign carcinoma. While with 42.8% in male squamous carcinoma was frequent, adenocarcinoma with 57.8% in female was frequent. The average survival was calculated as 18 months, median survival as 12 months (95& Cl 11-13 months) and the rate of 2 years survival as 33,4%. While surgical treatment were applied to 380 patients (20.3%), chemotherapy were applied to 1100 patients(58,8%) and palliative care were applied to 302(16,1%) patients. The 2 years survival time was found significantly high in patients received surgical treatment.(73% in spite of 23.3%)(p<0.0001). While the 2 years survival of patients receiving chemotherapy was calculated as 25,6%, the patients receiving palliative care was 20,5%(p=0.08).The median survival time was found 28,4 months in patients receiving surgical treatment, patients receiving chemotherapy 14 months and palliative care was 11.5 months .The patients received neoadjuvan therapy lived 31months. Evaluation made as multivariate analyses; age, gender, with histological type, the tretament variables one by one were found effective on survival as p=0.0001 level.

      Conclusion:
      It was obtained that the patients diagnosed with lung cancer in our hospital, after they diagnosed they lived averagely 16 months. The patients received surgical treatment with 73%,with 2 years time survival lived significantly more than the other treatments.

  • +

    P2.06 - Poster Session with Presenters Present (ID 467)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
    • Presentations: 1
    • +

      P2.06-044 - Frequency of Mutations and Related Factors in Lung Adenocarcinoma Cases in Turkey (ID 5291)

      14:30 - 15:45  |  Author(s): S. Altin

      • Abstract
      • Slides

      Background:
      Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 receptor tyrosine kinase (ROS1) gene mutations in lung adenocarcinoma (LA) cases give an opportunity to use some of targeted therapy agents. The aim of this study is to obtain EGFR, ALK and ROS1 gene mutation frequencies in Turkey and to examine the factors affecting these frequencies.

      Methods:
      EGFR, ALK, ROS1 mutation analyses were examined in a total of 971 LA cases; 745 men (76.7%), and 226 women (23.3%) diagnosed in 12 hospitals from different districts of Turkey were enrolled in the study. The demographic characteristics, smoking status, asbestos exposure history, radiological findings associated with asbestos exposure (AE) were investigated with relation to the frequencies of EGFR, ALK and ROS1 gene mutations. In the univariate analysis of the study data chi-square and t-tests were used. To determine the independent factors associated with gene mutations, multivariate logistic regression model was created with the variables that give p <0.10 level of significance in univariate analysis.

      Results:
      The mean age of 971 patients was 60.8±9.8 years (range:23-91). Smoking rate was 92.6% in men, 42.5% in women (p<0.001). The number of patients with AE history was 279 (28.7%) and the number of patients with radiologic findings associated with AE was 114 (11.7%). The frequencies of EGFR, ALK and ROS1 mutations were 15.9% (152/956), 3.3% (26/768) and 1.6% (6/379), respectively. Female patients were more likely to have EGFR mutations compared with male patients (37.8% versus 9.3%; p<0,001). Never-smokers had higher incidence of EGFR mutations than smokers (39.6% versus 10.3%; p<0.001). The patients with radiological findings of AE had a 24.6% rate of EGFR mutations compared with a 14.7% rate of patients with no radiological findings (p=0.007). ALK rearrengement was detected in patients with younger age, having history of AE or radiological findings associated with AE (11.1%; p<0.001, 5.9%; p=0.014, 6.7%; p=0.044, respectively). No associated factor was found with ROS1 fusion frequency.

      Conclusion:
      To have a relationship between radiographic findings associated with AE or AE history and EGFR and ALK mutation frequencies is an original finding. The obtained results will be useful in the discussion of standards of treatment with the new agents and pathogenesis. *This study was carried out through the project named as “Network cooperation for the management of environmental and occupational exposure to mineral fibers induced pulmonary pathologies” which was supported by General Directorate of Health Researches, Republic of Turkey, Ministry of Health.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.07 - Poster Session with Presenters Present (ID 493)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Regional Aspects/Health Policy/Public Health
    • Presentations: 1
    • +

      P3.07-017 - Joinpoint Regression Analysis of Lung Cancer Mortality, Turkey (ID 4939)

      14:30 - 15:45  |  Author(s): S. Altin

      • Abstract

      Background:
      It is important to investigate the variation of the deaths due to lung cancer in time.The aim of this study is to investigate the variations in the rate of deaths due to lung cancer in Turkey.

      Methods:
      Data on lung cancer mortality during 2009-2014 years were extracted from the Turkish Statistical Instıtute and Turkey Public Health Agency mortality data based on Internal Classification of Diseases 10(ICD-10)codes C32-C34.For each gender, age group-spesific and standardised rates were calculated by direct standardized method (using the world standard population).These were expressed as rates/100,000 persons.The temporal trend in lung cancer mortality rates were tested for age,gender and methods using Joinpoint Regression Analysis.In joinpoint regression analysis,the best-fitting points where the rate changes significantly (increase or decrease) are chosen.Each joinpoint indicates a statistically significant change in trend,and annual percentage change(APC) is computed for each of trend by means of generalised lineer models assuming a Possion distrubition.

      Results:
      119.778 deaths due to lung cancer were recorded; 85.50%(n=102409) of the were in men,14.50% (n=17369)were in women. The mean of crude rate of lung cancer mortality is from 2009(23.77 deaths/100.000) to 2014(26.78 deaths/100.000) 26.19 in 100.000, in men 44.00 in women 7.74.The mean of lung cancer age-spesific standardised rates from 2009(49.47 deaths/100.000)to 2014(54.57 deaths/100.000) is 52.50 in 100.000,in men 45.83 and in women 6.62. Lung cancer mortality rates shows a significant increase between 2009-2014.The rates of lung cancer mortality,between 2009-2014 with 4.2% (%95 Confidence Interval: 3.2 to 5.3)showed an important increase annually(p<0.001).During working period, throughout men the variation 4.1%(2.8 to 5.5)in the lung cancer mortality rates were significant(p<0.001).Similar situation was in women with 5.0%(3.7 to 6.4)(p<0.001)The deaths due to lung cancer in young age(under 44 years )in women(5.27%)is more than men(2.59%)(p<0.001). The decrease of -5.4%(-1.5 to 5.3)in deaths due to lung cancer seen in young men(under 45 years) within years was not significant(p=0.20). Similarly in women with same age the variation 3.1%(-2.7 to 9.3 was not significant(p=0.30). The variation in men between the ages45-64 deaths due to lung cancer within years 1.5%(-0.3 to 3.4)was not significant(p=0.10).Unlike in women in this age group with 3.8% increase(2.2-5.5)showed significance(p<0.001). The increase in deaths due to lung cancer seen in men in 65 years of age and over 4.4%(3.6-5.2)was significant(p<0.001).With the same result in women 2.6%increase(1.1-4.1)was seen(p<0.001).

      Conclusion:
      Even though deaths due to lung cancer show non-significant decrease in male, shows significantly increase above 65 years of age. Increase in lung cancer in young women is remarkable.